FDA Removes Partial Clinical Hold on Trials for OncoMed’s Ipafricept

Drug Industry Daily
A A
Drugmaker OncoMed expects to resume enrollment and dosing of new patients for its experimental cancer drug ipafricept in the coming weeks, after the FDA lifted a partial hold on its clinical trials.

To View This Article:

Login

Subscribe To Drug Industry Daily